JAAD Comment Puts Isotretinoin–Antidepressant Suicide Signals Under the Lens

The Journal of the American Academy of Dermatology published a formal comment in November 2026 (Volume 95, Issue 5) on a descriptive analysis of FDA Adverse Event Reporting System data examining suicidality reports in acne patients treated with isotretinoin and concomitant antidepressants.

The comment, authored by Dandan Li, Jianxing Zhou and Xiaoyuan Zheng, engages directly with the original study by Nie et al (2026), titled "Suicidality reports in acne patients treated with isotretinoin and concomitant antidepressants: A descriptive analysis of FDA Adverse Event Reporting System Data."

Why this exchange matters for prescribers

Isotretinoin remains the most effective systemic therapy for severe acne, but its psychiatric risk profile has been debated for decades. The pairing in the underlying study — isotretinoin plus antidepressants — matters because it isolates a specific clinical scenario: patients whose depression or anxiety was already pharmacologically treated before or during the acne course.

When a journal of JAAD's stature hosts a peer-reviewed comment on a pharmacovigilance paper, it signals that the methodology behind the signal deserves scrutiny. FAERS data are spontaneous reports. They carry well-known limitations: no denominator, reporting bias, missing causality and duplication. Any disproportionality signal drawn from them is hypothesis-generating, not confirmatory.

Li, Zhou and Zheng's decision to write formally about the Nie et al analysis places the debate where dermatologists actually encounter it — in the exam room, with an acne patient who is already on an SSRI or SNRI and needs a definitive acne treatment.

What does this change for clinical practice?

For now, nothing in the isotretinoin label or in standard screening practice changes on the basis of a journal comment. What the exchange does is sharpen the questions prescribers should ask of FAERS-derived psychiatric signals:

• Were suicidality reports in patients on both drugs distinguishable from reports in patients on isotretinoin alone?
• How did the descriptive analysis handle confounding by indication — that is, depression severe enough to require antidepressants?
• Do the reporting patterns support surveillance changes, or do they mainly reflect the well-documented baseline psychiatric burden in this cohort?

These are exactly the kinds of methodological points that a formal comment in JAAD is designed to surface.

The bigger picture

The comment arrives in Volume 95, Issue 5, of JAAD — a journal that dermatologists read for exactly this type of signal evaluation. The original Nie et al paper and this response together form a published dialogue on one of the most litigated safety questions in dermatology: whether isotretinoin itself contributes to suicidality, or whether the reports track with the psychiatric comorbidity already present in the treated population.

For clinicians, the practical takeaway is a familiar one, restated with fresh data in view: screen for depression history, document baseline psychiatric status, coordinate with the prescribing psychiatrist or primary care physician when antidepressants are on board, and counsel patients with specifics rather than blanket warnings.

Whether regulatory agencies act on this literature exchange is a separate question — spontaneous-report analyses and the comments they generate rarely move labels on their own. But with Li, Zhou and Zheng now on record in JAAD, the isotretinoin–antidepressant suicidality question has a published, peer-reviewed counterpoint that future meta-analyses and safety reviews will have to cite.